Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune((R)) vaccine

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to...

Descripción completa

Detalles Bibliográficos
Autores: Santos, Fernanda Nunes, Borja-Cabrera, G. P., Miyashiro, L. M., Grechi, J., Reis, Alexandre Barbosa, Moreira, M. A. B., Martins Filho, Olindo Assis, Luvizotto, M. C. R., Menz, I., Pessôa, L. M., Gonçalves, P. R., Palatnik, M., Palatnik-de-Sousa, C. B.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2007
País:Brasil
Institución:Fundação Oswaldo Cruz (FIOCRUZ)
Repositorio:Repositório Institucional da FIOCRUZ (ARCA)
Idioma:inglés
OAI Identifier:oai:arca.fiocruz.br:icict/53596
Acceso en línea:https://arca.fiocruz.br/handle/icict/53596
Access Level:acceso abierto
Palabra clave:FML-vaccine
Immunotherapy
Leishmune((R)) vaccine
Canine visceral leishmaniasis
Leishmania chagasi
Kala-azar
Saponin
Quillaja saponaria molina
QS21
03 Saúde e Bem-Estar
Descripción
Sumario:Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.